Last €0.59 EUR
Change Today -0.001 / -0.17%
Volume 0.0
HG6 On Other Exchanges
Symbol
Exchange
Berlin
OTC US
As of 2:04 AM 07/10/14 All times are local (Market data is delayed by at least 15 minutes).

mayne pharma group ltd (HG6) Snapshot

Open
€0.59
Previous Close
€0.59
Day High
€0.59
Day Low
€0.59
52 Week High
03/24/14 - €0.67
52 Week Low
08/28/13 - €0.34
Market Cap
343.8M
Average Volume 10 Days
0.0
EPS TTM
--
Shares Outstanding
586.7M
EX-Date
03/3/11
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for MAYNE PHARMA GROUP LTD (HG6)

Related News

No related news articles were found.

mayne pharma group ltd (HG6) Related Businessweek News

No Related Businessweek News Found

mayne pharma group ltd (HG6) Details

Mayne Pharma Group Limited, a specialty pharmaceutical company, develops, manufactures, distributes, and markets proprietary and generic products using oral drug delivery systems. The company’s products include various capsules and tablets, such as Astrix, a form of aspirin indicated for chronic use in cardiovascular or cerebrovascular disease; Doryx, a delayed release oral formulation of doxycycline used to treat acne and infections, or as an anti-malarial; Eryc/Erymax, a delayed release erythromycin used in the treatment of various bacterial infections; and Kadian and Kapanol, a sustained release oral formulation of morphine used in the management of moderate to severe chronic pain. Its products also comprise SUBACAP, a formulation of itraconazole used to treat fungal infections; Magnoplasm paste for initial treatment in abscesses, boils, and blind pimples and carbuncles; and Urocarb tablets indicated for acute postoperative and postpartum non-obstructive urinary retention, as well as for neurogenic bladder with retention; and Percutane Pain Relief cream and Percutane Sports cream that are natural plant based creams. In addition, the company offers active pharmaceutical ingredients with off-patent drugs or new chemical entities; analytical development, formulation development, logistics, manufacturing, packaging, pre-clinical and clinical development, process development and scale up, quality assurance, preformulation, stability, and validation services; and contract manufacturing services to third-party customers, as well as manufactures and out-licenses proprietary pharmaceuticals to marketing and distribution partners. It sells its products directly or through distribution partners primarily in Australia, the United States, and Korea. The company was formerly known as Halcygen Pharmaceuticals Limited and changed its name to Mayne Pharma Group Limited in November 2010. Mayne Pharma Group Limited is headquartered in Salisbury, Australia.

500 Employees
Last Reported Date: 09/24/13

mayne pharma group ltd (HG6) Top Compensated Officers

Chief Executive Officer, Managing Director an...
Total Annual Compensation: A$544.3K
Chief Financial Officer and Company Secretary
Total Annual Compensation: A$397.6K
Vice President of Operations
Total Annual Compensation: A$89.3K
President of Mayne Pharma USA
Total Annual Compensation: A$180.8K
National Sales & Marketing Director
Total Annual Compensation: A$93.9K
Compensation as of Fiscal Year 2013.

mayne pharma group ltd (HG6) Key Developments

Mayne Pharma Seeks Acquisitions

Mayne Pharma Group Limited (ASX:MYX) plans to make acquisitions. Expansion of Mayne Pharma's U.S. product portfolio will come through organic development and bolt-on acquisitions, said Stefan Cross, President of Mayne Pharma.

Mayne Pharma Appoints Blake Cullen as Vice President of Business Development for Its U.S. Generic Products Division

Mayne Pharma has appointed Blake Cullen as vice president of business development for its U.S. generic products division. Prior to joining Mayne Pharma, he held business development roles with Rhodes Pharma, Libertas Pharma, Paddock Labs and Prasco Labs. He also served as general counsel at Qualitest Pharmaceuticals.

Mayne Pharma Group Ltd Announces Earnings Results for the Six Months Ended December 31, 2013

Mayne Pharma Group Ltd. announced earnings results for the six months ended December 31, 2013. For the period, the company's net profit was $8.43 million compared with a net loss of $2.55 million for the first half of last year. Operating profit was $10.64 million against an operating loss of $1.48 million a year ago. Revenue rose 158% to $70.75 million from $27.37 million. Basic earnings per share were 1.50 cents against a loss per basic share of 1.00 cents a year ago. The group result reflects the impacts from recent business and product acquisitions, new product launches, increased market penetration of existing products and more favorable exchange rates.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
HG6:GR €0.59 EUR -0.001

HG6 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for HG6.
View Industry Companies
 

Industry Analysis

HG6

Industry Average

Valuation HG6 Industry Range
Price/Earnings 64.3x
Price/Sales 4.1x
Price/Book 3.9x
Price/Cash Flow 40.4x
TEV/Sales 3.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MAYNE PHARMA GROUP LTD, please visit www.maynepharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.